Skip to content
Research/Longevity Diagnostics/Targeted Genotyping of PNPLA3 and HSD17B13

Targeted Genotyping of PNPLA3 and HSD17B13

Targeted genotyping of PNPLA3 rs738409 and HSD17B13 rs72613567 involves analyzing specific genetic variants associated with liver health. These variants can influence the risk of liver disease, making them important for personalized health strategies and longevity optimization. Understanding these genetic markers can help tailor interventions to mitigate liver-related health risks.

Intelligence Profile

Science

Targeted genotyping of PNPLA3 and HSD17B13 involves identifying genetic variants associated with metabolic dysfunction-associated steatotic liver disease (MASLD), which includes conditions like nonalcoholic fatty liver disease (NAFLD).

PNPLA3 (Patatin-like phospholipase domain-containing protein 3):

The PNPLA3 gene is linked to lipid metabolism. Variants such as the I148M polymorphism are associated with increased liver fat content and inflammation (Gut and liver, 2025). These genetic differences can affect how fat is stored and processed in the liver, contributing to higher susceptibility to liver diseases (Clinical gastroenterology and hepatology, 2024).

HSD17B13 (17-beta-hydroxysteroid dehydrogenase 13):

The HSD17B13 gene encodes an enzyme involved in steroid metabolism. Certain variants, particularly loss-of-function mutations, have been shown to reduce the risk of liver inflammation and fibrosis (Journal of hepatology, 2025). However, this protective effect is not universal, as studies show variability among populations (Journal of clinical and experimental hepatology, 2024).

Mechanism of Action:

  • PNPLA3: Variants lead to altered lipid processing, where fat accumulation and inflammatory responses in liver cells contribute to disease progression.

  • HSD17B13: Variants affect steroid and lipid interactions within the liver, with some loss-of-function mutations reducing disease severity by lowering fibrosis risks (International journal of molecular sciences, 2026).

By understanding these genetic influences, targeted genotyping helps in assessing individual risks for MASLD and may guide personalized treatment approaches.

Disclaimer: This content is for informational purposes only and is not medical advice. For medical concerns, please consult a healthcare professional.